Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

A clinical psychologist helped me change my approach to bedtime for better rest. If you're always tired, this simple guide is for you.

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

Study reveals that sleep traits predict over 15% of body characteristics across 15 physiological systems, with visceral fat, ...

The global sleep apnea devices market is set to expand at a steady CAGR of 9.5%, growing from USD 8.2 billion in 2023 to USD ...

On today’s CT BUZZ, Host Natasha Lubczenko sat down with Dr. Zach Korwin, owner of Sleep Stratford, to discuss an innovative ...

According to statistics by the American Association of Medicine, the disorder sleep apnea affects approximately 30 million US ...

A new survey published today reveals that 70% of women report that their sleep is impacting their mental health, while a ...